Abstract
Cysteine proteases are one of the largest groups of proteases and are involved in many important biological functions in all kingdoms of life. They are virulence factors of a range of eukaryotic, bacterial and viral pathogens and are involved in host invasion, pathogen replication and disruption of the host immune response. Their activity is regulated by a range of protease inhibitors. This review discusses the various families of cysteine protease inhibitors, their different modes of inhibition and their evolutionary relationships. These inhibitors as well as the recent discovery of propeptide and propeptide-like inhibitors provide insights into the structures that are important for particular inhibitory mechanisms, thus forming the foundation for the design of future therapeutics.
Keywords: Cysteine proteases, cysteine protease inhibitors, therapeutics, infectious diseases, pathogen replication, immune response, evolutionary relationships, substrate specificity, nutrient acquisition, non-structural viral protein, Trypanosoma cruzi, Trypanosoma brucei, stefins, phytocystatins, factor aplha, interferon-γ-activated macrophages, nitric oxide, interleukin-10, β-immunoglobulin, proteolysis, BCPI
Current Protein & Peptide Science
Title: Cysteine Protease Inhibitors: from Evolutionary Relationships to Modern Chemotherapeutic Design for the Treatment of Infectious Diseases
Volume: 11 Issue: 8
Author(s): E. C.Y. Toh, N. L. Huq, S. G. Dashper and E. C. Reynolds
Affiliation:
Keywords: Cysteine proteases, cysteine protease inhibitors, therapeutics, infectious diseases, pathogen replication, immune response, evolutionary relationships, substrate specificity, nutrient acquisition, non-structural viral protein, Trypanosoma cruzi, Trypanosoma brucei, stefins, phytocystatins, factor aplha, interferon-γ-activated macrophages, nitric oxide, interleukin-10, β-immunoglobulin, proteolysis, BCPI
Abstract: Cysteine proteases are one of the largest groups of proteases and are involved in many important biological functions in all kingdoms of life. They are virulence factors of a range of eukaryotic, bacterial and viral pathogens and are involved in host invasion, pathogen replication and disruption of the host immune response. Their activity is regulated by a range of protease inhibitors. This review discusses the various families of cysteine protease inhibitors, their different modes of inhibition and their evolutionary relationships. These inhibitors as well as the recent discovery of propeptide and propeptide-like inhibitors provide insights into the structures that are important for particular inhibitory mechanisms, thus forming the foundation for the design of future therapeutics.
Export Options
About this article
Cite this article as:
C.Y. Toh E., L. Huq N., G. Dashper S. and C. Reynolds E., Cysteine Protease Inhibitors: from Evolutionary Relationships to Modern Chemotherapeutic Design for the Treatment of Infectious Diseases, Current Protein & Peptide Science 2010; 11 (8) . https://dx.doi.org/10.2174/138920310794557646
DOI https://dx.doi.org/10.2174/138920310794557646 |
Print ISSN 1389-2037 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5550 |

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Elastin-Like Recombinamers As Smart Drug Delivery Systems
Current Drug Targets Mn-SOD and Chronic Inflammation of Gastric Mucosa
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Flavonoid-Based Cancer Therapy: An Updated Review
Anti-Cancer Agents in Medicinal Chemistry 1-[4-(2-Dimethylaminoethoxy)phenylcarbonyl]-3,5-Bis(3,4,5-Trimethoxybenzylidene)- 4-Piperidone Hydrochloride and Related Compounds: Potent Cytotoxins Demonstrate Greater Toxicity to Neoplasms than Non- Malignant Cells
Medicinal Chemistry Anti-Apoptotic Mechanisms of Drug Resistance in Cancer
Current Cancer Drug Targets Editorial (Mini Thematic Issue: Immunotherapy – A Pivotal Mechanism in the Fight of Cancer)
Reviews on Recent Clinical Trials The Use of the Inhibitory Receptors for Modulating the Immune Responses
Current Pharmaceutical Design Investigating ABCB1-Mediated Drug-Drug Interactions: Considerations for In vitro and In vivo Assay Design
Current Drug Metabolism Pseudogene PTENP1 Suppresses Gastric Cancer Progression by Modulating PTEN
Anti-Cancer Agents in Medicinal Chemistry Evidence of PKC Binding and Translocation to Explain the Anticancer Mechanism of Chlorogenic Acid in Breast Cancer Cells
Current Molecular Medicine Patent Selections:
Recent Patents on Regenerative Medicine Targeting Telomerase for Cancer Therapy
Current Cancer Therapy Reviews Anti-Metastatics: An Overview of Drug Candidates in Current Pipelines
Current Pharmaceutical Design Chemoprevention of Skin Carcinomas in High-Risk Transplant Recipients
Current Medicinal Chemistry Chemistry and Theranostic Applications of Radiolabeled Nanoparticles for Cardiovascular, Oncological, and Pulmonary Research
Current Topics in Medicinal Chemistry Targeting CD47 Inhibits Tumor Development and Increases Phagocytosis in Oral Squamous Cell Carcinoma
Anti-Cancer Agents in Medicinal Chemistry Cyclooxygenase-2 Inhibition and Gastric Cancer
Current Pharmaceutical Design MicroRNAs as Potential Therapeutic Agents in the Treatment of Myocardial Infarction
Current Vascular Pharmacology mTOR: A Novel Therapeutic Target for Diseases of Multiple Systems
Current Drug Targets Nanocellulose-based Delivery Systems and Cervical Cancer: Review of the Literature
Current Pharmaceutical Design